Mergers & Acquisitions
Report: Medtronic to pay $150M for wearable sensor maker Corventis
Updated May 20, 2014, at 2:45 p.m. with comment from Medtronic.
Report: Deals in the medical device sector rose 200% in Q1
Acquisition activity among medical device companies surged some 200% by value and 111% by volume during the 1st quarter compared with the same period last year, with medtech firms seeking both tuck-ins and more transformative deals aimed at navigating the new healthcare landscape, according to a PricewaterhouseCoopers report.
Ackman goes after Allergan CEO Pyott in Valeant/Pershing takeover bid
M&A: Medtech makers use acquisitions to fill niches
Medical device companies opted to fill in their portfolios with niche acquisitions during the 1st quarter, rather than venturing into new treatment areas or looking to diversify, according to a report by a healthcare investment bank.
Is Boston Scientific’s peripherals buy bad news for Cardiovascular Systems?
Boston Scientific’s (NYSE:BSX) $415 million acquisition of Bayer AG’s interventional unit is a strong move for the company, but it may bode ill for other peripheral players.
Boston Scientific bolsters peripheral business with $415M Bayer buy
Boston Scientific (NYSE:BSX) said it agreed to acquire Bayer AG’s interventional unit for $415 million, in a move to significantly bolster its own $200 million peripheral interventions business.
Steris closes $165M IMS buy, takes $20.5M charge for restructuring in Q4
M&A: Z-Medica nabs TAUREON’S Novacol hemostatic products
Connecticut-based Z-Medical announced this month that it acquired the Novacol resorbable hemostatic product line from rival TAUREON, headquartered in The Netherlands.
TAUREON said that it hopes to focus more on its core businesses, giving over the Novacol line to Z-Medica and its vast distribution network. The companies did not disclose the terms of the deal.